Nasioudis D, et al. - Researchers assessed if adjuvant chemotherapy had any benefit in primary mucinous ovarian carcinoma (MOC) by evaluating 4,811 patients diagnosed with stage I MOC between 2004 and 2015 found in the U.S National Cancer Database. Around one-third of patients with stage I MOC received adjuvant chemotherapy; receipt of chemotherapy was linked to stage IC, larger tumor size, and high tumor grade. The 5-year overall survival rate was 86.8% vs 89.7%, respectively, between patients who did vs did not receive chemotherapy, showing administration of chemotherapy in patients with early stage MOC was not related to better survival; this was true even after controlling for substage, patient age, type of insurance, tumor grade, performance of lymphadenectomy and the presence of co-morbidities.